Rx00013 - Allopurinol


Name:
Allopurinol
Rx ID:
Rx00013
Validation Level:
Phenomic Similarity:
0.486
Reference ID:
DB00437
Primary Indications:
Hyperuricemia; primary gout; secondary gout; primary uric acid nephropathy; secondary uric acid nephropathy; chemotherapy-induced hyperuricemia; recurrent renal calculi
Orphan Indications:
Chagas' disease; cutaneous leishmaniasis; visceral leishmaniasis; ex-vivo kidney preservation; kidney transplantation
Rare Indications:
Leukemia; lymphoma; solid tumor malignancies
Common Indications:
Primary gout; secondary gout; recurrent calcium oxalate calculi
Drug Interactions:
Acenocoumarol; Anisindione; Azathioprine; Cyclosporine; Dicoumarol; Mercaptopurine; Trandolapril Warfarin;
Food Interactions:
Avoid alcohol. Take with a full glass of water. Take with food.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00013
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
recurrent renal calculi primary gout 769 15291 12681 16.002 0 0.0
secondary gout primary gout 12681 12681 12681 318.187 0 0.0
chemotherapy-induced hyperuricemia primary gout 989 17817 12681 17.662 0 0.0
hyperuricemia primary gout 989 17817 12681 17.662 0 0.0
primary gout secondary gout 12681 12681 12681 318.187 0 0.0

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
HYPERURICEMIA LYMPHOMA 9.39e-10 1231, ABCG2, ACE, ADRB2, ADRB3, APOA4, APOE, COMT, CYBA, ESR1, GNB3, HLA-A, HLA-B, HLA-C, HLA-DRB1, IFNG, IL10, IL28B, IL6, INHBC, KDR, LRP2, MMP3, MTHFR, NOS3, PARD3B, PON1, PPARG, SERPINE1, TGFB1, TLR4, TNF, TYMS, XDH

Chemical, Pharmacological and Biological Annotations


ATC Code:
M04AA01
Brands:
Adenock (Tanabe); Allohexal; Alloril; Aluron; Milurit; Progout; Zyloric; Zyrik
Categories:
Gout Suppressants; Enzyme Inhibitors; Antimetabolites; Free Radical Scavengers
ChEBI ID:
40279
PubChem ID:
2094
KEGG Drug ID:
D00224
SMILE:
O=C1N=CN=C2NNC=C12
InChI:
1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
Classification:
Kingdom:
Organic Compounds
Superclass:
Heterocyclic Compounds
Class:
Pyrazolopyrimidines
Subclass:
Indication:
For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemi...
Click to show more...
Pharmacodynamics:
Allopurinol, a structural analog of the natural purine base hypoxanthine, is used to prevent gout and renal calculi due to either uric acid or calcium oxalate and to treat uric acid nephropathy, hyperuricemia, and some solid tumors.
Description:
A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [PubChem]
Mechanism:
Allopurinol and its active metabolite, oxypurinol, inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xant...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.1087 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org